In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glycomed Inc.

Division of Ligand Pharmaceuticals Inc.

Latest From Glycomed Inc.

A Really Near-Term Application for Discovery Technology: Momenta and Sandoz Attempt a Biogeneric

The press release was foggy; Sandoz Inc., the generics unit of Novartis AG, was teaming up with a biotech, Momenta Pharmaceuticals Inc. to commercialize "complex pharmaceutical products." Upon closer examination, the deal in fact has wide-ranging implications, representing the very real near-term possibility of a true generic biologic,
BioPharmaceutical

Glycomics: Sugar Coating is More than Decoration

By the mid 1990s, most of the early carbohydrate drug development companies were either defunct or had repositioned themselves. But academia continued to advance gycobiology analysis tools. Today, thanks to improved mass spec and bioinformatic methods, as well as newly-revealed structure-activity relationships, a new generation of glycomics companies has a chance to succeed where forebears failed.
BioPharmaceutical Research and Development Strategies

ChemoCentryx Inc.

Founded by chemokine pioneer and the discoverer of RANTES, Dr. Thomas Schall, ChemoCentryx is pursuing anti-infective and immunotherapy applications of chemokines and their receptors.
BioPharmaceutical

The New Deal Structures: The Recipe is Creativity

With capital markets depressed and internal R&D growing ever more expensive, biotech and Big Pharma need each other more than ever. But a new wave of skeptical drug partners are forcing humbled biotechs to write deals that minimize risk without driving down the deal's value.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ligand Pharmaceuticals Inc.
  • Senior Management
  • Brian Atwood, Pres. & CEO
    Tim Morris, Acting CFO & CAO
    Sam Teichman, MD, VP, R&D
  • Contact Info
  • Glycomed Inc.
    Phone: (510) 523-5555
    860 Atlantic Ave.
    Alameda, CA 94501
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register